Ramelteon is a melatonin receptor agonist used as a treatment for insomnia. It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration resulting in an over 100-fold increase in exposure. The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data. Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways. The main routes of metabolism included hydroxylation on the ethyl side chain and the benzylic position of the cyclopentyl ring, as assessed through enzyme kinetic measurements. Hydroxylation at the other benzylic position was observed in human intestinal microsomes. Ramelteon metabolism was catalyzed by CYP1A2, 2C19, and 3A4 as shown through the use of recombinant human P450 enzymes and specific inhibitors. In liver, CYP1A2, 2C19, and 3A4 were estimated to contribute 49%, 42%, and 8.6% respectively, whereas in intestine only CYP3A4
INTRODUCTION
The need to use more than one drug simultaneously in one patient (polypharmacy) can arise for two main reasons: (a) some diseases call for the use of more than one drug for effective treatment (e.g. cancer chemotherapy) and (b) some patients, especially the elderly, have more than one condition each requiring their own drug treatment. However, the simultaneous use of more than one drug can also lead to drug-drug interactions (DDI), in which the exposure to one agent can be altered by the other. This can potentially lead to undesired side-effects, more severe safety concerns, and in some cases even decreased efficacy. The understanding that has been achieved regarding the role of the cytochrome P450 enzyme superfamily and the roles of specific P450 enzymes in the clearance of drugs has led to an ability to leverage in vitro drug metabolism data in the prediction of drug-drug interactions (Obach, 2009; Houston and Galetin, 2008; Huang, et al., 2008) . Considerable effort is expended in the search for new pharmacotherapies to design molecules that will be less likely to cause or be subject to DDI.
Among the large number of drugs available, there is a small subset wellestablished as perpetrators of DDI known to cause large (i.e. >5-fold) increases in exposures to other drugs. Examples include ketoconazole, itraconazole, ritonavir, clarithromycin, paroxetine among others. These perpetrators of DDI are either potent inhibitors or mechanism-based inactivators of specific P450 enzymes, and their dosing regimens used in therapy yield concentrations in vivo that are high enough to have a profound effect on their target P450 enzyme. While dose and potency drive the potential magnitude of DDI caused by a perpetrator, for a victim drug the magnitude of the interaction is driven mostly by the fraction of the clearance of the drug that is mediated This article has not been copyedited and formatted. The final version may differ from this version. by the affected enzyme. For example, if 80% of the clearance of a victim drug is mediated by a single enzyme and if that enzyme were completely inhibited by administration of a perpetrator drug, then the largest increase in exposure will be 5-fold. This is explained by the Rowland-Matin equation which relates the magnitude of DDI to inhibitory potency (K i ), concentration of the perpetrator ([I]), and the fraction of the victim drug that is cleared by the affected enzyme (f CL ) (Rowland and Matin, 1973 In most cases, the victim drugs have multiple clearance pathways, and even if one pathway were to be completely inhibited, there will be remaining pathways of clearance operating that will dampen the overall effect. Thus, observations of DDI of greater than 10-fold are infrequent.
Ramelteon (Figure 1 ), introduced into clinical practice in 2005, is an agonist of the melatonin receptors MT 1 and MT 2 and is used to treat insomnia. Within the product label, a DDI study is briefly described in which coadministration of fluvoxamine leads to a 190-fold increase in the AUC of ramelteon (U.S. FDA, 2008) , which perhaps represents the largest DDI recorded to date for any drug. The mechanism underlying this massive DDI is not described, with the exception that ramelteon is described as being metabolized by CYP1A2 and it is known that fluvoxamine can cause DDI with other drugs known to be cleared by this enzyme, such as theophylline (Rasmussen, et al., 1997; Yao, et al., 2001; Orlando, et al., 2006) and tizanidine (Granfors, et al., 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. However, despite the fact that fluvoxamine is known to inhibit CYP1A2, whether this is actually the mechanism underlying its effect on ramelteon is not known.
According to the Rowland-Matin equation, the f CL value for CYP1A2 for ramelteon would need to be very close to unity (i.e. 0.995), with fluvoxamine causing complete inhibition of CYP1A2 to elicit a 190-fold increase in exposure. However, it is also known that fluvoxamine is a potent inhibitor of other P450 enzymes, such as CYP2C19 (Christensen, et al., 2002; Yasui-Furukori, et al., 2004) . Fluvoxamine can also mildly impact drugs cleared by CYP3A4 (e.g. buspirone; Lamberg, et al., 1998) , even though its intrinsic inhibitory potency for CYP3A4 is less than that for other P450 enzymes. This is likely due to an effect of very high concentrations of fluvoxamine in the gut causing an impact of drugs subject to high first-pass intestinal extraction catalyzed by CYP3A4.
Thus, it is possible that the DDI for ramelteon caused by fluvoxamine is due to simultaneous inhibition of multiple enzymes, and it could be the case that ramelteon metabolism is carried out by these same enzymes that are sensitive to fluvoxamine. To be able to successfully extrapolate in vitro inhibition data to the in vivo fluvoxamineramelteon DDI, as complete a picture of ramelteon clearance pathways as is possible must be obtained. Data on the clearance pathways of ramelteon in human are scant, and it has been stated that it is primarly cleared by P450 mediated metabolism with less than 0.1% of the drug excreted unchanged (Karim, et al., 2006; Rozerem Product Label, 2008) . The objectives of the present study were to determine the in vitro metabolite profile of ramelteon, to quantitatively determine the enzymes involved in each metabolic pathway, and to attempt to extrapolate the in vivo DDI from in vitro data using various modeling approaches.
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METHODS
In Vitro Metabolite Profiling of Ramelteon. The metabolite profile for ramelteon (10 μM) was determined in pooled human liver microsomes (1.0 mg/mL), pooled human intestinal microsomes (1.0 mg/mL), and heterologously expressed recombinant human cytochrome P450 enzymes (50 pmol/mL). Incubations were carried out in 1.0 mL KH 2 PO 4 (0.1M; pH 7.5) containing MgCl 2 (3.3 mM) and NADPH (1.3 mM) for 30 min followed by addition of five volumes of CH 3 CN. The precipitated material was removed by spinning in a centrifuge at 1700 x g, and the supernatant was evaporated in vacuo.
The residue was reconstituted in 0.2 mL 1% HCOOH in 10% CH 3 CN, spun in a microfuge at 14000 rpm and the clarified supernatant was analyzed by HPLC-MS as described below.
Biosynthesis and Isolation of Ramelteon Metabolites. Ramelteon (50 μM) was incubated with rat (0.5 mg/mL) and dog (0.5 mg/mL) liver microsomes, 1.3 mM NADPH, and 3.3 mM MgCl 2 in 0.1 M KH 2 PO 4 , pH 7.5. The incubation was carried out at 37 o C open to air for 1 hr, followed by addition of CH 3 CN (40 mL), and removal of precipitated protein by spinning in a centrifuge at 1700 x g for 5 min. The supernatant was subject to vacuum centrifugation for 1.5 hr, addition of 0.1% HCOOH to a total volume of 100 mL, and the material spun in a centrifuge at 40000 x g for 30 min. The supernatant was applied to a Varian Polaris C18 column (4.6 x 250 mm; 5μ particle size) through a Jasco pump at 0.8 mL/min. The column was moved to a gradient HPLC-MS system described below.
Fractions were collected every 20 sec and fractions containing individual metabolites were pooled followed by evaporation of the solvent in vacuo for subsequent NMR analysis for structure elucidation and determination of the concentration.
This article has not been copyedited and formatted. The final version may differ from this version. Eppendorf microfuge at 14000 rpm for 4 min. Supernatants were transferred to HPLC vials and 0.08 mL was injected. The effect of inhibitors was also examined on ramelteon first-order consumption using a substrate concentration of 1 μM, microsomal protein at 2 mg/mL, and incubation times of 0, 5, 15, and 30 min.
Microsome Binding. Ramelteon (10 μM) was mixed with pooled human liver microsomes (range of protein concentrations = 0.03 to 2.0 mg/mL) in 0.1 M KH 2 PO 4 pH 7.5 containing MgCl 2 (3.3 mM), and subjected to equilibrium dialysis. Dialysis was carried out for 4.5 hr at 37 o C in a Spectrum apparatus rotated at 20 rpm. SpectraPor membranes (#4) with a molecular weight cutoff of 12-14kDa were employed. Following the dialysis, the resulting samples were analyzed for ramelteon using an HPLC-MS method described below.
This article has not been copyedited and formatted. The final version may differ from this version. Orbitrap mass spectrometer in order to obtain exact mass data. Ionization and fragmentation conditions were similar to above, with the instrument operated in FTMS mode at a resolution setting of 30000.
Three different conditions were used, depending on the experimental endpoint.
For metabolite profiling, metabolite purification, and structure elucidation, the system consisted of a Varian Polaris C18 column (4.6 x 250 mm; 5 μ) held at at 0.8 mL/min 10% B for 5 min. This was followed by a linear gradient to 60%B at 45 min, rinsing of the column at 90%B for 5 min, and reequilibration to initial conditions for 10 min. The effluent was split with ~60 μL/min introduced into the source of the mass spectrometer.
The MS was operated in the data-dependent scanning mode, over a range of m/z 200 to 400.
For quantitation of ramelteon metabolites, the system consisted of a Varian Polaris C18 column (4.6 x 250 mm; 5 μ) held at at 0.8 mL/min 25% B for 5 min. This
This article has not been copyedited and formatted. The final version may differ from this version. (12.5 min); and internal standard: m/z 314→268 (22.6 min). Quantitation was accomplished using a standard curve ranging from 0.01 to 10 μM, using 1/x weighting.
The standards used were those biosynthesized and isolated, with quantitation of the mother stock solutions being done with quantitative proton NMR spectroscopy.
For quantitation of ramelteon, a Phenomenex phenylhexyl column (4.6 x 50 mm; 3 μ) was used. Initial mobile phase composition was held for 0.5 min at 50%B at a flow rate of 0.8 mL/min, followed by a linear gradient to 90%B at 2 min, held at 90%B for 0.5 min, and reequilibration to initial conditions for 1.5 min. The effluent was split with ~60 Transformed NMR spectra were phase corrected and manually baseline corrected.
Standard concentrations for metabolites ([C] metabolite ) were calculated using the equation:
Eq 2 in which [C] reference signal is the concentration represented by the computer generated signal for one proton as calibrated from the 10 mM maleic acid reference solution, A reference signal is the integrated peak area for that signal, n is the number of protons in the resonance signal used for the metabolite, A metabolite is the integrated peak area for that metabolite signal.
Enzyme Kinetic and Inhibition Data. Enzyme kinetic parameters and IC 50 values were generated using Sigma Plot (v9). The most appropriate enzyme kinetic model was selected based on the visual inspection of the data plotted on Eadie-Hofstee plots This article has not been copyedited and formatted. The final version may differ from this version. 
or Michaelis-Menten equation with a second, non-saturable component (CL int (2)):
For some reactions, saturation kinetics were not observable, so the data were fit to a straight line with a slope equal to the intrinsic clearance, CL int .
Prediction of In Vivo Pharmacokinetic and Drug-Drug Interactions from In Vitro Data.
The prediction of in vivo clearance was performed using the well-stirred model of hepatic extraction:
The value for CL' int was scaled from in vitro intrinsic clearance data using scaling factors of 45 mg microsomal protein per gram of liver and 20 grams of liver per kg body weight.
Hepatic blood flow (Q h ) was 21 mL/min/kg, and binding values were obtained from published information (see Results).
The value for intestinal extraction (F g ) of an oral dose of ramelteon was estimated using the following equation:
This article has not been copyedited and formatted. The final version may differ from this version. in which F represents the absolute bioavailability value, F a is the fraction absorbed, and fraction evading hepatic extraction is the function of aforementioned hepatic blood flow, Q h , and intravenous blood clearance (CL iv ).
F g was also estimated from scaling the in vitro CL' int,gut from intestinal microsomes:
Eq. 7 using a gut plasma flow (Q g ) of 3.5 mL/min/kg. The CL' int,gut value was estimated by using the hepatic CL' int generated from recombinant CYP3A4 divided by a factor of 94 to account for the amount of CYP3A4 in the intestine relative to the liver. Values of 3 mg intestinal micosomes per gram tissue and 30 gm tissue per kg body weight were used in scaling from intestinal in vitro CL' int (Chiba, et al., 1997) .
The prediction of DDI for three simultaneous clearance pathways when the inhibitor and substrate are coadministered orally was done using the following equation:
The first term represents the impact on hepatic intrinsic clearance, which in this case is the impact on the three enzymes CYP1A2, CYP2C19, and CYP3A4. Figure S4 ).
Fragmentation was identical to metabolite B suggesting that the position of hydroxylation is also on the dihydrofuran ring. The two protons on the carbon adjacent to the furan oxygen remained at 4.20 and 4.46 ppm, while the third at carbon-1 was now at 5.36 ppm.
This article has not been copyedited and formatted. The final version may differ from this version. The COSY spectrum showed coupling between these protons, and heteronuclear coupling was consistent with the assignment. Figure S6 ). Attempts to isolate these showed that in aqueous solution they were interconverted. The major fragment ion at m/z 159 is indicative of a dehydrated indenofuran ring. Due to the inter-conversion, the metabolites were isolated as a diasteromeric mixture and 1 H-NMR data indicated that the position of hydroxylation is at benzylic carbon-6. The methine proton on carbon 6 was observed at 4.86 and 5.01 in a 1:1 mixture, and 2D COSY data were consistent with the structure assignment. Table 1 , and the substrate saturation plots depicted in Figure 5 .
The greatest intrinsic clearance was observed for formation of metabolites A, E, and F, which accounted for 85% of total intrinsic clearance. Michaelis constants for five of the metabolites were in the range of 17 to 39 μM, while for metabolites C and G these values were over 10-fold greater. Formation of metabolite H did not show saturation, precluding estimation of a K M value.
In pooled intestinal microsomes, metabolite C had the greatest intrinsic clearance, accounting for 42% of the total, followed by metabolites G, E, and F; these four accounted for 86% of total intrinsic clearance in the intestine. For metabolites C and G, K M values in the intestine and liver were similar, whereas K M values for the other metabolites were considerably greater. Metabolite A, which was major in liver, was barely measureable in intestine.
This article has not been copyedited and formatted. The final version may differ from this version. was also determined. These two concentrations were selected to be reflective of those measured in plasma and estimated to occur in tissues of first-pass following oral administration of 200 mg/day QD. The effects of these inhibitors are listed in Table 3 . The effect of these inhibitors was also measured when total ramelteon consumption was measured at a substrate concentration of 1 μM (Table 3) μM, respectively), consistent with these two metabolites being primarily generated by
CYP3A4.
This article has not been copyedited and formatted. The final version may differ from this version. Estimation of Ramelteon Pharmacokinetics From In Vitro Data. The pharmacokinetics of ramelteon in humans has been briefly described (refer to Summary Basis of Approval Document, U.S. FDA). The total clearance following intravenous clearance is listed as 916 mL/min (13 mL/min/kg, assuming a 70 kg body weight). In that document, it was reported that the red blood cells contained 25% of the total ramelteon in blood, which after correction for a typical hematocrit value of 0.45, yields a blood/plasma ratio of 0.73.
Converting the plasma clearance of 13 mL/min/kg to the more physiologically meaningful blood clearance yields a value of 18 mL/min/kg, which approaches hepatic blood flow in humans (21 mL/min/kg). Plasma protein binding was reported as 82%;
correction for the blood/plasma ratio yields a free fraction in blood of 0.25. with gut plasma flow yielded a value for F g of 0.76. Assuming that CYP3A4 is the only enzyme contributing to ramelteon metabolism in the gut, and using the hepatic CL' int generated from recombinant CYP3A4 divided by a factor of 94 which accounts for the amount of CYP3A4 in the intestine relative to the liver yielded a CL' int value for intestine of 2.2 mL/min/kg body weight which converts to a value for F g of 0.61. Considering that coadministration of ketoconazole with ramelteon causes only a 1.4-fold increase in mean C max (see below) and that orally administered ketoconazole causes nearly complete inhibition of gut CYP3A4 activity, values of F g of 0.61 or 0.76 are more in line with this effect than the value of 0.15 that is back-calculated from F, F a , and F h . Since CL iv is close to Q h any error will be magnified in the back-calculated value of F h which could be overestimated and thus cause an understimation of F g .
This article has not been copyedited and formatted. The final version may differ from this version. The prediction of DDI for three simultaneous clearance pathways when the inhibitor and substrate are coadministered orally was done using Equation 8.
In this equation, the three enzymes shown to be involved in the metabolism of ramelteon in liver, along with an intestinal term, are included. However, it is possible that there is a fraction ramelteon clearance that does not occur via these enzymes and tissues, which represents a limitation of the approach and the equation used for these predictions.
Values for K i were those previously determined and successfully used in the prediction of DDI for over 100 drugs (Obach, et al., 2006 ; Table 5 ). The relative contributions of CYP1A2, 2C19, and 3A4 to the metabolism of ramelteon were estimated from the enzyme data generated above. The CL' int for each of the eight metabolites in HLM was This article has not been copyedited and formatted. The final version may differ from this version. used to determine the % contribution of each pathway to total CL' int , and the individual contribution by each of the three enzymes to each pathway was determined separately and re-summed to determine the relative contribution of each enzyme to total CL' int (Table 6 ). These were combined with the value of 0.61 for F g described above.
The predicted DDIs for ramelteon caused by ketoconazole, fluconazole, and fluvoxamine are listed in Table 7 
DISCUSSION
It is highly desirable to be able to quantitatively predict of DDI from in vitro inhibition data. Such data are routinely gathered during research on new drugs and in general have been successfully leveraged to predict DDI (Obach, et al., 2005) . To date, the effect of fluvoxamine on the pharmacokinetics of ramelteon represents the greatest magnitude for a DDI ever described, at 128-fold (or 190-fold, when using least-square averages). The mean AUC(0-∞) of a single dose of 16 mg ramelteon increased from 7.98
(+/-8.86) ng-hr/mL to 1021 (+/-393) ng-hr/mL when given after 4 days of 100 mg BID fluvoxamine (Summary Basis of Approval Document, U.S. FDA). Thus, the fluvoxamine-ramelteon combination represents an extreme example to test whether such a large interaction could be projected from in vitro inhibition data. In order to attempt this, a comprehensive examination of the clearance pathways of the victim drug must be done, since in theory greater than 99% of the clearance must be entirely inhibited to yield a DDI of greater than 100-fold. In this report, six metabolic pathways were shown for ramelteon in human liver microsomes. This is more than the three pathways previously reported in which hydroxylation on the ethyl (corresponding to metabolite A), oxidation and ring opening of the furan (a downstream metabolite from metabolite B), and oxidation of the cyclopentyl ring (corresponding to metabolite H) were described (Karim, et al., 2006) . This biosynthesis and isolation of the eight metabolites, and use of quantitative NMR to establish concentrations of stock solutions for these metabolites permitted determination of enzyme kinetic parameters for each ramelteon metabolic pathway.
This article has not been copyedited and formatted. The final version may differ from this version. The metabolism by CYP1A2 has been previously described (Simpson and Curran, 2008) . Fluvoxamine is known to inhibit this enzyme potently in vitro and in vivo, however in order to explain the >100-fold interaction it would be necessary that CYP1A2
be virtually the only enzyme involved in ramelteon clearance. This is clearly not the case because co-administration of ramelteon with ketoconazole and fluconazole both yield DDI (1.82 and 2.36-fold increases respectively) while neither of these drugs is known to affect CYP1A2 cleared drugs (Naline, et al., 1988; Konishi, et al; 1994) . However, in the present study it was shown that both CYP2C19 and CYP3A4 also contribute to ramelteon metabolism. This is consistent with the effects of ketoconazole and fluconazole on ramelteon pharmacokinetics. When the enzyme kinetic data were used to estimate the fraction of ramelteon cleared by CYP2C19 and CYP3A4 and these values were used in the estimating of the DDI caused by fluconazole and ketoconazole, the estimates were close to the actual values (Table 7) .
The in vitro enzyme kinetic data, the calculated contributions of CYP1A2, 2C19, and 3A4 to total ramelteon metabolism, the relative contribution of liver and intestine to ramelteon metabolism, and the inhibitory potency values for fluvoxamine were used to make an estimate of the impact of fluvoxamine on ramelteon pharmacokinetics. The estimate was 11-fold, which is a large effect, but it fell short of the actual DDI of greater than 100-fold (Table 7 ). The hepatic CYP1A2 activity is estimated at 1/94 th of normal when fluvoxamine is administered (Table 7) . If ramelteon were only cleared by CYP1A2, then this would yield an estimated 94-fold increase in exposure. However, this is not the case, since CYP2C19 and CYP3A4 also contribute to ramelteon clearance.
While the prediction of 11-fold is still a remarkable magnitude of DDI, the reason(s) for fold. An explanation for why the fluvoxamine-ramelteon DDI is underestimated is not known. The value for in vivo hepatic concentration of fluvoxamine used was 1.63 μM, which is an estimate from the dose, absorption, free plasma fraction, and absorption rate (Obach, et al., 2006) . It is possible that if fluvoxamine is subject to active uptake into the liver that the free intracellular concentration is actually higher. However, the concentration would need to be approximately 40-fold greater to explain the discrepancy, which is unlikely (Brown, et al., 2007) . Another possibility is that ramelteon has another as yet unknown clearance pathway that is potently inhibited by fluvoxamine, but there is no evidence to support this. Finally, fluvoxamine had been reported to show timedependent inhibition of recombinant CYP3A4 coexpressed with cytochrome b 5 , with K I and k inact values of 3.7 μM and 0.05/min respectively (Jones, et al., 2007) . However, in our own investigations, we did not observe time-dependent inhibition of CYP3A4 activity in human liver microsomes. It has been our observation that, despite the correlation between reversible inhibition data in liver microsomes and recombinant expressed P450 enzymes, time-dependent inhibition kinetics in these two systems do not match well (unpublished observations) and such differences have been shown by others as well for P450 inactivators (Polasek and Miners, 2008) . However, if fluvoxamine were a mechanism-based inactivator of CYP3A4, then it would be reasonably expected that the This article has not been copyedited and formatted. The final version may differ from this version. In summary, the in vitro metabolism for ramelteon in human liver microsomes, intestinal microsomes, and recombinant cytochrome P450 enzymes was examined.
Ramelteon shows six metabolic pathways which were catalyzed by CYP1A2, 2C19, and This article has not been copyedited and formatted. The final version may differ from this version.
